Skip Navigation

European Journal of Heart Failure 2006 8(5):532-538; doi:10.1016/j.ejheart.2006.04.004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lainchbury, J. G.
Right arrow Articles by Richards, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lainchbury, J. G.
Right arrow Articles by Richards, A. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society of Cardiology

NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial

John G. Lainchbury, Richard W. Troughton, Christopher M. Frampton, Timothy G. Yandle, Amjad Hamid, M. Gary Nicholls and A. Mark Richards*

The Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine and Health Sciences, University of Otago, and the Department of Cardiology Christchurch Hospital, Christchurch, New Zealand

* Corresponding author. Tel.: +64 3 364 1116; fax: +64 3 364 1115. E-mail address: barbara.griffin{at}chmeds.ac.nz


   Abstract

Background: How best to decide when to introduce drugs and what doses are optimal in individual patients with chronic heart failure (CHF), is unclear.

Aims: We will determine whether titration of drug treatment according to plasma NTproBNP is superior regarding clinical outcomes to intensive standardised clinical assessment; whether either of the regimens noted above is superior to usual care; and whether age alters the relative efficacy of NTproBNP guided treatment.

Methods: We will randomise 360 patients, stratified by age, to drug treatment directed by plasma NTproBNP, to intensive standardised clinical assessment, or to usual care. The primary outcome is total mortality, and secondary outcomes include death plus hospital admission for any cardiovascular event plus episodes of outpatient decompensated heart failure. Analyses will be conducted at the end of one and two years.

Results: 308 patients have been recruited, the majority being in NYHA functional class II, 60.6% being >75 years. The entry plasma NTproBNP level is 238, 50–1250 pmol/l, median and range, approximately 400–11,000 pg/ml.

Conclusion: sWe describe details of a study to test the potential utility of serial measurements of NTproBNP in adjusting the drug treatment of patients with CHF. Projected completion date is 2007.

Key Words: Chronic heart failure • BNP • NTproBNP • Drug therapy

Received December 12, 2005; Revised March 8, 2006; Accepted April 13, 2006


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Clin. Chem.Home page
A. K. Saenger, D. A. Dalenberg, S. C. Bryant, S. K. Grebe, and A. S. Jaffe
Pediatric Brain Natriuretic Peptide Concentrations Vary with Age and Sex and Appear to Be Modulated by Testosterone
Clin. Chem., October 1, 2009; 55(10): 1869 - 1875.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
J. G.F. Cleland, A. P. Coletta, A. Torabi, and A. L. Clark
Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF
Eur J Heart Fail, August 1, 2009; 11(8): 802 - 805.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
L. Frankenstein, A. Remppis, J. Frankenstein, G. Hess, D. Zdunek, K. Slottje, H. A. Katus, and C. Zugck
Variability of N-Terminal Probrain Natriuretic Peptide in Stable Chronic Heart Failure and Its Relation to Changes in Clinical Variables
Clin. Chem., May 1, 2009; 55(5): 923 - 929.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
C. Vassalle and M. G. Andreassi
Genetic Polymorphisms of the Natriuretic Peptide System in the Pathogenesis of Cardiovascular Disease: What Lies on the Horizon?
Clin. Chem., May 1, 2009; 55(5): 878 - 887.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
P. Ray, S. Delerme, P. Jourdain, and C. Chenevier-Gobeaux
Differential diagnosis of acute dyspnea: the value of B natriuretic peptides in the emergency department
QJM, November 1, 2008; 101(11): 831 - 843.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
J. P. Goetze, U. Dahlstrom, J. F. Rehfeld, and U. Alehagen
Impact of Epitope Specificity and Precursor Maturation in Pro-B-Type Natriuretic Peptide Measurement
Clin. Chem., November 1, 2008; 54(11): 1780 - 1787.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
A. Maisel, C. Mueller, K. Adams Jr., S. D. Anker, N. Aspromonte, J. G.F. Cleland, A. Cohen-Solal, U. Dahlstrom, A. DeMaria, S. Di Somma, et al.
State of the art: Using natriuretic peptide levels in clinical practice
Eur J Heart Fail, September 1, 2008; 10(9): 824 - 839.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. W. Waldo, J. Beede, S. Isakson, S. Villard-Saussine, J. Fareh, P. Clopton, R. L. Fitzgerald, and A. S. Maisel
Pro-B-Type Natriuretic Peptide Levels in Acute Decompensated Heart Failure
J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1874 - 1882.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A M. Richards
Variability of NT-proBNP levels in heart failure: implications for clinical application
Heart, August 1, 2007; 93(8): 899 - 900.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
J. Hogenhuis, A. A. Voors, T. Jaarsma, A. W. Hoes, H. L. Hillege, J. A. Kragten, and D. J. van Veldhuisen
Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure
Eur J Heart Fail, August 1, 2007; 9(8): 787 - 794.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
L. G. Olsson, K. Swedberg, J. G.F. Cleland, P. A. Spark, M. Komajda, M. Metra, C. Torp-Pedersen, W. J. Remme, A. Scherhag, P. Poole-Wilson, et al.
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a {beta}-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial
Eur J Heart Fail, August 1, 2007; 9(8): 795 - 801.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
T. Breidthardt, K. Laule, A.-H. Strohmeyer, C. Schindler, S. Meier, M. Fischer, A. Scholer, M. Noveanu, M. Christ, A. P. Perruchoud, et al.
Medical and Economic Long-term Effects of B-Type Natriuretic Peptide Testing in Patients with Acute Dyspnea
Clin. Chem., August 1, 2007; 53(8): 1415 - 1422.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure
Circulation, July 31, 2007; 116(5): e99 - e109.
[Full Text] [PDF]


Home page
JAMAHome page
M. A. Konstam
Natriuretic Peptides and Cardiovascular Events: More Than a Stretch
JAMA, January 10, 2007; 297(2): 212 - 214.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2575 - 2583.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.